However, the phase III trial of a peptide vaccine targeting multiple antigens (gp100, MART-1, and tyrosinase) and GM-CSF against resected high-risk melanoma patients did not improve the relapse-free survival and overall survival, indicating that the immunogenicity of the tumor type is not the only factor for predicting peptide vaccines responses. The gene discussed is PMEL; the disease is melanoma.